Research Tools

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors in Europe. A subscription to this report includes 2 waves of data, collected biannually.

Blood-based biomarkers are emerging in neurodegenerative disease testing, enabling earlier, less invasive detection and monitoring. This analysis maps activity across clinical trials, publications, pharma pipelines, and routine clinical use to benchmark key biomarkers, disease focus areas, and leading industry players driving this shift.

After several years of muted growth from 2022 to 2025, the next-generation sequencing (NGS) market is finally set up for a recovery. We forecast that the ~$7.3B WW NGS manufacturer market (2025) will grow 7% p.a. to reach $8.9B in 2028.

The first edition of this report provides a comprehensive overview of the global real-world data and evidence (RWD/E) market from 2025 to 2030. RWD has become increasingly central in life sciences decision-making, empowering organizations to generate insights that enhance research, clinical development, and commercial decision-making. The market is expanding as data types diversify, spanning electronic health records, claims, imaging, and omics, and as analytics become more advanced through AI and federated data approaches. Key players include data aggregators, generators (e.g., Guardant Health, Natera), enablers (e.g., COTA, Aetion), as well as players that span multiple functions (e.g., Tempus, Flatiron, NashBio).